Intended for UK Healthcare Professionals only. This website contains promotional information.

Adverse events and prescribing information can be found at the bottom of the page

IOPIDINE®
Keeping intraocular
pressure in check

Iopidine® effectively controls intraocular pressure (IOP), supporting successful glaucoma treatment before and after surgery.1

An elderly person smiling
A picture of the IOPIDINE® 5 mg/ml bottle

IOPIDINE® 5 mg/ml

A picture of the IOPIDINE® 1% w/v sachet

IOPIDINE® 1% w/v
Pouch comes in a box of 2 or 12

IOPIDINE® (apraclonidine) is an α2-adrenergic receptor agonist that is able to reduce intraocular pressure (IOP) and prevent IOP spikes in both normotensive and glaucomatous eyes.1

Iopidine comes in two dosages with different indications:

IOPIDINE® 5 mg/ml is indicated for short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional IOP reduction to delay laser treatment or glaucoma surgery.2

IOPIDINE® 1% is indicated to control or prevent post-surgical elevations in IOP that occur in patients after anterior segment laser surgery. (Clinical trials have been conducted in trabeculoplasty, iridotomy and capsulotomy).3

A picture of the IOPIDINE® 5 mg/ml bottle and its packaging

IOPIDINE® 5 mg/ml

For patients with chronic glaucoma on maximally tolerated medical therapy, where there is a desire to delay surgical intervention, IOPIDINE® 5 mg/ml is the α2adrenergic receptor agonist proven to be effective in reducing IOP and delaying surgery, with benefits seen within 1 hour and for up to 1 month, without significantly affecting heart rate or blood pressure.1,2

Learn more
A picture of the IOPIDINE® 1% w/v sachet and its packaging

Pouch comes in a box of 2 or 12

IOPIDINE® 1%

For patients with glaucoma undergoing anterior segment laser surgery who are at risk of dangerous postprocedure intraocular pressure spikes, IOPIDINE® 1% is the α2-adrenergic receptor agonist proven to control or prevent post-surgical IOP spikes by reducing IOP within the first hour after surgery, without significantly affecting heart rate or blood pressure.1,3,4†

Learn more

†Study investigating IOP elevations after anterior
segment laser surgery (n=66).

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Essential Pharma at essentialpharmaUK@EU.ProPharmaGroup.com.

Prescribing Information Iopidine® 0.5%
Prescribing Information Iopidine® 1%
References
  1. Scuderi G et al. Expert Rev Ophthalmol. 2008;3: 149–153.
  2. IOPIDINE 5 mg/ml Summary of Product Characteristics https://www.medicines.org.uk/emc/product/14408/smpc/print December 2022.
  3. IOPIDINE 1% Summary of Product Characteristics https://www.medicines.org.uk/emc/product/14407/smpc/print December 2022.
  4. Yüksel N et al. Int Ophthalmol. 1992;16:337–342.

Your message was successfully sent. We will be in touch soon.

There was a problem trying to send your message. Please try again.